North America Clinical Trial Imaging Market is expected to grow with the CAGR of 6.9% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/north-america-clinical-trial-imaging-market

North America clinical trial imaging market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in North America clinical trial imaging market are introducing strong range of products provider along with receiving large number of FDA & CE mark approvals for launching new products into the market. For instance,

• In April 2019, IXICO PLC announced that they have done contracts with two biopharmaceutical companies for providing its imaging technology services which support study in Huntington's Disease (HD) along with phase 3 studies in one of the rare neurological disease. By this contract the company has enhanced their credibility in the market.

Navitas Life Sciences is the dominating player in North America clinical trial imaging market. The other key players existing in the market includes BioTelemetry, Inc, IXICO plc, Resonance Health, Bioclinica, ICON plc, Radiant Sage LLC, Quotient Sciences, worldcare Clinical, Cardiovascular Imaging Technologies, Intrinsic Imaging, ERT Clinical, Perspectum Diagnostics and Parexel International Corporation among others.

Navitas Life Sciences:

Navitas Life Sciences headquartered in New Jersey, U.S. The company focuses on providing clinical, regulatory and safety solutions and services. The company also has wide service portfolio including clinical, regulatory, safety, consulting, technology, nets among which clinical is the market focused category.

For instance,

• In May 2019, Navitas Life Cycle announced the acquisition of KAI Research which strengthens its expertise in pain, diabetes, infectious diseases, and mental health and intends to create an enterprise to deliver and initiate trial outcomes

The company also has wide global presence across North America, Asia, Europe, and South America.

BioTelemetry, Inc.:

BioTelemetry, Inc. headquartered in Pennsylvania, U.S. The company focuses on delivery of health information in order to improve quality of life at affordable cost of care. The service categories include heart monitoring, clinical research, global partnerships, health management and clinical research is the market focused category.

The company has wide presence across U.S., Europe. The various subsidiaries of the company include CardioNet, Inc. (U.S.), VirtualScopics, Inc. (U.S.), Telcare (U.S.), BioTelemetry Research (U.S.), Cardiocore, LLC (U.S.) and others.

RESONANCE HEALTH:

RESONANCE HEALTH headquartered in Burswood, Australia was founded in 2000. The company engages in the development and delivery of non-invasive medical imaging software and services. The company offers wide product portfolio categories including FerriScan MRI measurement of liver iron concentration, cardiac T2 with FerriScan, HepaFat-Scan MRI measurement of liver fat, bone marrow R2-MRI, and quality assured service delivery among which FerriScan MRI measurement of liver iron concentration, cardiac T2 with FerriScan, HepaFat-Scan MRI Measurement of liver fat, bone marrow R2-MRI are the market focuses categories.

For instance,

• In January 2019, Resonance Health announced that they have entered into an agreement with EnvoyAI to distribute its FerriSmart product in U.S. market, the product have received FDA regulatory clearance. After this agreement the company has expanded their business in U.S. market.

The company has wide presence across South America, North America, Europe, Asia-Pacific, Middle East and Africa. The company has various subsidiaries which includes Resonance Health Analysis Services Pty Limited (Australia), IVB Holdings Pty Ltd (Australia), Resonance USA Inc (U.S.)